Text Size

Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00110214
First received: May 4, 2005
Last updated: May 28, 2013
Last verified: May 2013
History of Changes
Results First Received: March 7, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Conditions: Adenocarcinoma of the Prostate
Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Stage IV Prostate Cancer
Interventions: Drug: docetaxel
Other: placebo
Drug: prednisone
Biological: bevacizumab
Other: laboratory biomarker analysis
Other: pharmacogenomic studies

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Between May 2005 and December 2007, 1,050 participants were recruited and randomized

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Docetaxel + Placebo Standard treatment Docetaxel: 75 mg/m2 by IV over 1 hour for 21 days, Prednisone: 5mg orally twice per day Placebo
Docetaxel + Bevacizumab Std Tx + monoclonal antibody therapy Docetaxel: 75 mg/m2 by IV over 1 hour for 21 days, Prednisone: 5mg orally twice per day Bevacizumab: 15 mg/kg IV every 3 weeks

Participant Flow:   Overall Study
    Docetaxel + Placebo     Docetaxel + Bevacizumab  
STARTED     526     524  
COMPLETED     17     21  
NOT COMPLETED     509     503  
Never started treatment                 21                 20  
Disease progression or death                 260                 151  
Adverse Event                 115                 192  
Refused further treatment                 52                 65  
Other (not specified)                 61                 75  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Docetaxel + Placebo Standard treatment Docetaxel: 75 mg/m2 by IV over 1 hour for 21 days, Prednisone: 5mg orally twice per day Placebo
Docetaxel + Bevacizumab Std Tx + monoclonal antibody therapy Docetaxel: 75 mg/m2 by IV over 1 hour for 21 days, Prednisone: 5mg orally twice per day Bevacizumab: 15 mg/kg IV every 3 weeks
Total Total of all reporting groups

Baseline Measures
    Docetaxel + Placebo     Docetaxel + Bevacizumab     Total  
Number of Participants  
[units: participants]
 		  526     524     1050  
Age  
[units: years]
Median ( Inter-Quartile Range ) 		  69.3  
  ( 62.4 to 75.6 )   		  68.8  
  ( 63.0 to 74.4 )   		  69.0  
  ( 62.7 to 75.2 )  
Age, Customized  
[units: participants]
 		     
< 65 years     174     179     353  
>=65 years     352     345     697  
Gender  
[units: participants]
 		     
Female     0     0     0  
Male     526     524     1050  
Region of Enrollment  
[units: participants]
 		     
United States     526     524     1050  
24-month predicted survival probability  
[units: participants]
 		     
<10%     95     94     189  
10-29.9%     184     183     367  
>=30%     247     247     494  
Prior history of arterial events  
[units: participants]
 		     
Yes     42     37     79  
No     484     487     971  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Overall Survival   [ Time Frame: Duration of study (up to 5 years) ]
  Show Outcome Measure 1

2.  Secondary:   Proportion of Participants Who Experienced at Least a 50% Post-therapy PSA (Prostate-Specific Antigen) Decline   [ Time Frame: Duration of study (up to 5 years) ]
  Show Outcome Measure 2

3.  Secondary:   Progression-free Survival (PFS)   [ Time Frame: Duration of study (up to 5 years) ]
  Show Outcome Measure 3

4.  Secondary:   Proportion of Participants Who Experience (Maximum) Grade 3 or Higher Toxicities   [ Time Frame: During treatment (up to 2 years) ]
  Show Outcome Measure 4


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: William Kevin Kelly, DO
Organization: Thomas Jefferson University
e-mail: wm.kevin.kelly@jefferson.edu


No publications provided


Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00110214     History of Changes
Other Study ID Numbers: NCI-2012-02814, CALGB-90401, CDR0000427290, U10CA031946
Study First Received: May 4, 2005
Results First Received: March 7, 2013
Last Updated: May 28, 2013
Health Authority: United States: Food and Drug Administration